Gefitinib for advanced non‐small cell lung cancer
EHA Sim, IA Yang, R Wood‐Baker… - Cochrane Database …, 2018 - cochranelibrary.com
Background The role of gefitinib for the treatment of advanced non‐small cell lung cancer
(NSCLC) is evolving. We undertook a systematic review to evaluate the available evidence …
(NSCLC) is evolving. We undertook a systematic review to evaluate the available evidence …
A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy …
FA Shepherd, J Pereira, TE Ciuleanu… - Journal of Clinical …, 2004 - ascopubs.org
7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …
Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations
K Asami, T Okuma, T Hirashima, M Kawahara, S Atagi… - Lung Cancer, 2013 - Elsevier
BACKGROUND: Gefitinib is an effective treatment for patients with non-small cell lung
cancer who harbor activating epidermal growth factor receptor (EGFR) mutations. However …
cancer who harbor activating epidermal growth factor receptor (EGFR) mutations. However …
Gefitinib: a review of its use in adults with advanced non-small cell lung cancer
S Dhillon - Targeted oncology, 2015 - Springer
Gefitinib (Iressa®) is a selective small-molecule epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (EGFR TKI) indicated for the treatment of adults with locally …
tyrosine kinase inhibitor (EGFR TKI) indicated for the treatment of adults with locally …
Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations
Gefitinib is effective in treating advanced non-small cell lung cancer (NSCLC), especially in
Asian patients in whom the prevalence of epidermal growth factor receptor (EGFR) mutation …
Asian patients in whom the prevalence of epidermal growth factor receptor (EGFR) mutation …
First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology
M Sebastian, A Schmittel, M Reck - European respiratory …, 2014 - Eur Respiratory Soc
Recent advances in understanding the mechanisms of nonsmall cell lung cancer (NSCLC)
has led to the development of targeted treatments, including the reversible epidermal growth …
has led to the development of targeted treatments, including the reversible epidermal growth …
Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non–small-cell lung cancer and poor performance …
Purpose To compare gefitinib with placebo in chemotherapy naïve patients with advanced
non–small-cell lung cancer (NSCLC) and poor performance status. Patients and Methods …
non–small-cell lung cancer (NSCLC) and poor performance status. Patients and Methods …
Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review
X Chen, Y Liu, OD Røe, Y Qian, R Guo, L Zhu, Y Yin… - PloS one, 2013 - journals.plos.org
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI),
gefitinib and erlotinib have been tested as maintenance therapy in patients with advanced …
gefitinib and erlotinib have been tested as maintenance therapy in patients with advanced …
Treatment of EGFR-mutant lung cancers after progression in patients receiving first-line EGFR tyrosine kinase inhibitors: a review
Z Piotrowska, LV Sequist - Jama Oncology, 2016 - jamanetwork.com
Importance Patients withEGFR-mutant lung cancer benefit from treatment with EGFR
inhibitors such as erlotinib, gefitinib, and afatinib, but outcomes are limited by the eventual …
inhibitors such as erlotinib, gefitinib, and afatinib, but outcomes are limited by the eventual …
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of …
VA Miller, V Hirsh, J Cadranel, YM Chen, K Park… - The lancet …, 2012 - thelancet.com
Summary Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical
activity when tested in EGFR mutant models with mutations that confer resistance to EGFR …
activity when tested in EGFR mutant models with mutations that confer resistance to EGFR …